{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T12:07:38Z","timestamp":1769342858994,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004847","name":"Zahedan University of Medical Sciences","doi-asserted-by":"publisher","award":["1192"],"award-info":[{"award-number":["1192"]}],"id":[{"id":"10.13039\/501100004847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/aims<\/jats:title>\n                <jats:p>One of the opportunistic pathogens which cause serious problems in the human immune system is <jats:italic>Toxoplasma gondii,<\/jats:italic> with toxoplasma encephalitis (TE) seen in patients affected by it. The treatment of these patients is limited, and if not treated on time, death will be possible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, the effects of the treatment with different doses of fluconazole (FLZ) in combination with the current treatment of acute toxoplasmosis on reducing the mortality rate and the parasitic load in the murine model in vivo were studied. The mice were treated with different doses of fluconazole alone, sulfadiazine, and pyrimethamine plus fluconazole. A day after the end of the treatment and 1 day before death, the mice\u2019s brains were collected, and after DNA extraction and molecular tests, the parasite burden was detected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study showed that a 10-day treatment with 20\u00a0mg\/kg of fluconazole combined with sulfadiazine and pyrimethamine 1.40\u00a0mg\/kg per day affected acute toxoplasmosis and reduced the parasitic load significantly in brain tissues and also increased the survival rate of all mice in this group until the last day of the study, in contrast to other treatment groups. These results also indicate the positive effects of combined therapy on <jats:italic>Toxoplasma gondii<\/jats:italic> and the prevention of relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Reducing the parasitic burden and increasing the survival rate were more effective against acute toxoplasmosis in the combined treatment of different doses of fluconazole with current treatments than current treatments without fluconazole. In other words, combination therapy with fluconazole plus pyrimethamine reduced the parasitic burden in the brain significantly, so it could be a replacement therapy in patients with intolerance sulfadiazine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-021-00537-3","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:02:55Z","timestamp":1625040175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine"],"prefix":"10.1186","volume":"26","author":[{"given":"Sekandarpour","family":"Sina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jafari Modrek","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafiei","family":"Reza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadiha","family":"Anita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etemadi","family":"Soudabeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirahmadi","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.ijpara.2008.03.007","volume":"38","author":"JP Dubey","year":"2008","unstructured":"Dubey JP, Jones JL. Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol. 2008;38:1257\u201378.","journal-title":"Int J Parasitol"},{"issue":"7","key":"537_CR2","first-page":"441","volume":"20","author":"M Zarean","year":"2017","unstructured":"Zarean M, Shafiei R, Gholami M, Fata A, Rahmati Balaghaleh M, Karimi A, et al. Seroprevalence of anti-toxoplasma gondii antibodies in healthy voluntary blood donors from Mashhad City, Iran. Arch Iran Med. 2017;20(7):441\u20135.","journal-title":"Arch Iran Med"},{"key":"537_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3347\/kjp.2016.54.1.93","volume":"54","author":"G Shen","year":"2016","unstructured":"Shen G, Wang X, Sun H, Gao Y. Seroprevalence of Toxoplasma gondii infection among HIV\/AIDS patients in Eastern China. Korean J Parasitol. 2016;54:93.","journal-title":"Korean J Parasitol"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s12639-020-01238-0","volume":"44","author":"A Asadi","year":"2020","unstructured":"Asadi A, Tavakoli Kareshk A, Sharifi I, Firouzeh N. Murine cathelicidin: as a host defensive response against Leishmania major infection. J Parasit Dis. 2020;44:633\u20138.","journal-title":"J Parasit Dis"},{"issue":"2","key":"537_CR5","first-page":"68","volume":"6","author":"R Shafiei","year":"2011","unstructured":"Shafiei R, Riazi Z, Sarvghad MR, Galian SM, Mahmoudzadeh A, Hajia M. Prevalence of IgG and IgM anti-Toxoplasma gondii antibodies in HIV positive patients in northeast of Iran. Iran J Pathol. 2011;6(2):68\u201372.","journal-title":"Iran J Pathol"},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijpddr.2012.12.002","volume":"3","author":"C Doliwa","year":"2013","unstructured":"Doliwa C, Xia D, Escotte-Binet S, Newsham EL, Aubert D, Randle N, et al. Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE). Int J Parasitol Drugs Drug Resist. 2013;3:35\u201344.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"537_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/pim.12306","volume":"38","author":"L Wang","year":"2016","unstructured":"Wang L, Lu G, Zhou A, Han Y, Guo J, Zhou H, et al. Evaluation of immune responses induced by rhoptry protein 5 and rhoptry protein 7 DNA vaccines against Toxoplasma gondii. Parasite Immunol. 2016;38:209\u201317.","journal-title":"Parasite Immunol"},{"key":"537_CR8","first-page":"362","volume":"14","author":"S Shojaee","year":"2019","unstructured":"Shojaee S, Firouzeh N, Keshavarz H, Azami SJ-P, Salimi M, Mohebali M. Nanosilver colloid inhibits Toxoplasma gondii tachyzoites and bradyzoites in vitro. Iran J Parasitol. 2019;14:362.","journal-title":"Iran J Parasitol"},{"key":"537_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.envint.2015.07.022","volume":"84","author":"Z-F Chen","year":"2015","unstructured":"Chen Z-F, Ying G-G. Occurrence, fate and ecological risk of five typical azole fungicides as therapeutic and personal care products in the environment: a review. Environ Int. 2015;84:142\u201353.","journal-title":"Environ Int"},{"key":"537_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mycmed.2014.10.016","volume":"25","author":"TK Ngouana","year":"2015","unstructured":"Ngouana TK, Dongtsa J, Kouanfack C, Tonfack C, Fomena S, Malli\u00e9 M, et al. Cryptoccocal meningitis in Yaound\u00e9 (Cameroon) HIV infected patients: diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole. J Mycol Med. 2015;25:11\u20136.","journal-title":"J Mycol Med"},{"key":"537_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.39.1.1","volume":"39","author":"JH Rex","year":"1995","unstructured":"Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995;39:1.","journal-title":"Antimicrob Agents Chemother"},{"key":"537_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.fm.2015.07.005","volume":"52","author":"J Jur\u00e1nkov\u00e1","year":"2015","unstructured":"Jur\u00e1nkov\u00e1 J, Basso W, Neumayerov\u00e1 H, Frencov\u00e1 A, Bal\u00e1\u017e V, Deplazes P, et al. Predilection sites for Toxoplasma gondii in sheep tissues revealed by magnetic capture and real-time PCR detection. Food Microbiol. 2015;52:150\u20133.","journal-title":"Food Microbiol"},{"key":"537_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.exppara.2014.08.012","volume":"145","author":"LG Camossi","year":"2014","unstructured":"Camossi LG, Fornazari F, Richini-Pereira VB, da Silva RC, Cardia DFF, Langoni H. Immunization of Wistar female rats with 255-Gy-irradiated Toxoplasma gondii: preventing parasite load and maternofoetal transmission. Exp Parasitol. 2014;145:157\u201363.","journal-title":"Exp Parasitol"},{"key":"537_CR14","first-page":"125","volume":"27","author":"G Saadatnia","year":"2010","unstructured":"Saadatnia G, Haj Ghani H, Khoo BY, Maimunah A, Noordin R. Research note optimization of Toxoplasma gondii cultivation in VERO cell line. Trop Biomed. 2010;27:125\u201330.","journal-title":"Trop Biomed"},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.exppara.2012.12.011","volume":"133","author":"\u00c9S Martins-Duarte","year":"2013","unstructured":"Martins-Duarte \u00c9S, de Souza W, Vommaro RC. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model. Exp Parasitol. 2013;133:294\u20139.","journal-title":"Exp Parasitol"},{"key":"537_CR16","doi-asserted-by":"crossref","unstructured":"Firouzeh N, Asadi A, Kareshk AT. Nano amphotericin B: a good anti-leishmanial drug with effect on cathelicidin gene expression. J Parasit Dis. 2020:1\u20136.","DOI":"10.1007\/s12639-020-01308-3"},{"key":"537_CR17","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1128\/AAC.01657-09","volume":"54","author":"J-L Wang","year":"2010","unstructured":"Wang J-L, Chang C-H, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54:2409\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"537_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2165\/00003495-199550040-00007","volume":"50","author":"KL Goa","year":"1995","unstructured":"Goa KL, Barradell LB. Fluconazole. Drugs. 1995;50:658\u201390.","journal-title":"Drugs"},{"key":"537_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.exppara.2009.12.011","volume":"124","author":"\u00c9S Martins-Duarte","year":"2010","unstructured":"Martins-Duarte \u00c9S, Lemgruber L, de Souza W, Vommaro RC. Toxoplasma gondii: fluconazole and itraconazole activity against toxoplasmosis in a murine model. Exp Parasitol. 2010;124:466\u20139.","journal-title":"Exp Parasitol"},{"key":"537_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1574-6968.2008.01130.x","volume":"282","author":"\u00c9DS Martins-Duarte","year":"2008","unstructured":"Martins-Duarte \u00c9DS, De Souza W, Vommaro RC. Itraconazole affects Toxoplasma gondii endodyogeny. FEMS Microbiol Lett. 2008;282:290\u20138.","journal-title":"FEMS Microbiol Lett"},{"key":"537_CR21","doi-asserted-by":"publisher","first-page":"e21237","DOI":"10.1371\/journal.pone.0021237","volume":"6","author":"J Penna-Coutinho","year":"2011","unstructured":"Penna-Coutinho J, Cortopassi WA, Oliveira AA, Fran\u00e7a TCC, Krettli AU. Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS ONE. 2011;6:e21237.","journal-title":"PLoS ONE"},{"key":"537_CR22","doi-asserted-by":"crossref","unstructured":"Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31.","DOI":"10.1128\/CMR.00057-17"},{"key":"537_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01964458","volume":"10","author":"CU Foppa","year":"1991","unstructured":"Foppa CU, Bini T, Gregis G, Lazzarin A, Esposito R, Moroni M. A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. Eur J Clin Microbiol Infect Dis. 1991;10:187\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"537_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T-C Chou","year":"2006","unstructured":"Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621\u201381.","journal-title":"Pharmacol Rev"},{"key":"537_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0149-2918(96)80059-2","volume":"18","author":"HB Fung","year":"1996","unstructured":"Fung HB, Kirschenbaum HL. Treatment regimens for patients with toxoplasmic encephalitis. Clin Ther. 1996;18:1037\u201356.","journal-title":"Clin Ther"},{"key":"537_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1995-7645(14)60087-0","volume":"7","author":"Y Dadimoghaddam","year":"2014","unstructured":"Dadimoghaddam Y, Daryani A, Sharif M, Ahmadpour E, Hossienikhah Z. Tissue tropism and parasite burden of Toxoplasma gondii RH strain in experimentally infected mice. Asian Pac J Trop Med. 2014;7:521\u20134.","journal-title":"Asian Pac J Trop Med"},{"key":"537_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.vetpar.2012.11.016","volume":"193","author":"J Jur\u00e1nkov\u00e1","year":"2013","unstructured":"Jur\u00e1nkov\u00e1 J, Opsteegh M, Neumayerov\u00e1 H, Kova\u0159\u010d\u00edk K, Frencov\u00e1 A, Bal\u00e1\u017e V, et al. Quantification of Toxoplasma gondii in tissue samples of experimentally infected goats by magnetic capture and real-time PCR. Vet Parasitol. 2013;193:95\u20139.","journal-title":"Vet Parasitol"},{"key":"537_CR28","doi-asserted-by":"publisher","first-page":"e2973","DOI":"10.1371\/journal.pntd.0002973","volume":"8","author":"RM Andrade","year":"2014","unstructured":"Andrade RM, Chaparro JD, Capparelli E, Reed SL. Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. PLoS Negl Trop Dis. 2014;8:e2973.","journal-title":"PLoS Negl Trop Dis"},{"key":"537_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.exppara.2014.05.008","volume":"143","author":"A Daryani","year":"2014","unstructured":"Daryani A, Sharif M, Dadimoghaddam Y, Souteh MBH, Ahmadpour E, Khalilian A, et al. Determination of parasitic load in different tissues of murine toxoplasmosis after immunization by excretory\u2013secretory antigens using Real time QPCR. Exp Parasitol. 2014;143:55\u20139.","journal-title":"Exp Parasitol"},{"key":"537_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/infdis\/157.1.14","volume":"157","author":"C Harris","year":"1988","unstructured":"Harris C, Salgo MP, Tanowitz HB, Wittner M. In vitro assessment of antimicrobial agents against Toxoplasma gondii. J Infect Dis. 1988;157:14\u201322.","journal-title":"J Infect Dis"},{"key":"537_CR31","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1517\/14656566.6.13.2231","volume":"6","author":"PO Gubbins","year":"2005","unstructured":"Gubbins PO, Amsden JR. Drug\u2013drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother. 2005;6:2231\u201343.","journal-title":"Expert Opin Pharmacother"},{"key":"537_CR32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1124\/dmd.104.002998","volume":"33","author":"HR Winter","year":"2005","unstructured":"Winter HR, Unadkat JD. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005;33:969\u201376.","journal-title":"Drug Metab Dispos"},{"key":"537_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","volume":"59","author":"X-Q Li","year":"2003","unstructured":"Li X-Q, Bj\u00f6rkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P 450 s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003;59:429\u201342.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-021-00537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-021-00537-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-021-00537-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:16:52Z","timestamp":1625041012000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-021-00537-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1186\/s40001-021-00537-3","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"12 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Zahedan University of Medical Sciences (reference number: IR.ZAUMS.fm.REC.1396.503).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"That each author has seen and approved the content of the submitted manuscript. And every author agrees to publish the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"That any affiliations with a direct financial interest in the subject matter or materials discussed in this manuscript are disclosed. The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}